These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 17062831)
1. Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Baxter MS; Schroeder WS; Cheng Y; Bernstein ZP Ann Pharmacother; 2006 Nov; 40(11):2053-8. PubMed ID: 17062831 [TBL] [Abstract][Full Text] [Related]
2. [Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage]. Vyhovs'ka IaI; Karol' IuS; Fedak LM; Tsytsyk OI Lik Sprava; 2004; (7):77-81. PubMed ID: 15724622 [TBL] [Abstract][Full Text] [Related]
3. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Poon MC Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145 [TBL] [Abstract][Full Text] [Related]
4. Potential role of recombinant factor VIIa as a hemostatic agent. Hedner U; Erhardtsen E Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390 [TBL] [Abstract][Full Text] [Related]
5. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. Larsen OH; Stentoft J; Radia D; Ingerslev J; Sørensen B Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086 [TBL] [Abstract][Full Text] [Related]
6. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Wróbel G; Dobaczewski G; Patkowski D; Sokół A; Grotthus E Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):729-30. PubMed ID: 16933258 [TBL] [Abstract][Full Text] [Related]
7. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728 [TBL] [Abstract][Full Text] [Related]
8. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Goodnough LT Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417 [TBL] [Abstract][Full Text] [Related]
9. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Barnes C; Blanchette V; Canning P; Carcao M Transfus Med; 2005 Apr; 15(2):145-50. PubMed ID: 15859982 [TBL] [Abstract][Full Text] [Related]
10. Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia. James KM; Melikian CN; Chowdary P; Mallett SV Anesth Analg; 2008 Aug; 107(2):402-5. PubMed ID: 18633015 [TBL] [Abstract][Full Text] [Related]
11. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247 [TBL] [Abstract][Full Text] [Related]
12. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Gerotziafas GT; Zervas C; Gavrielidis G; Tokmaktsis A; Hatjiharissi E; Papaioannou M; Lazaridou A; Constantinou N; Samama MM; Christakis J Am J Hematol; 2002 Mar; 69(3):219-22. PubMed ID: 11891811 [TBL] [Abstract][Full Text] [Related]
13. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation. Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045 [TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation. Flynn JD; Pajoumand M; Camp PC; Jahania MS; Ramaiah C; Akers WS Ann Pharmacother; 2004 Oct; 38(10):1639-42. PubMed ID: 15340124 [TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Tranholm M; Rojkjaer R; Pyke C; Kristensen AT; Klitgaard B; Lollike K; Blajchman MA Thromb Res; 2003 Feb; 109(4):217-23. PubMed ID: 12757777 [TBL] [Abstract][Full Text] [Related]
16. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Murkin JM Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007 [TBL] [Abstract][Full Text] [Related]
17. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Kessler C Intensive Care Med; 2002 Oct; 28 Suppl 2():S228-34. PubMed ID: 12404091 [TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. Coppola A; Simone CD; Palmieri NM; Coppola D; Lanza F; Ruosi C; Amoriello A; Di Minno G Blood Coagul Fibrinolysis; 2007 Mar; 18(2):199-201. PubMed ID: 17287639 [TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa in the treatment of bleeding. Midathada MV; Mehta P; Waner M; Fink LM Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250 [TBL] [Abstract][Full Text] [Related]
20. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. Lauritzen B; Tranholm M; Ezban M J Thromb Haemost; 2009 Apr; 7(4):651-7. PubMed ID: 19175492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]